Our group has developed a platform to target high-grade gliomas based on IL13Rα2 expression by genetically modifying T cells to express an IL13Rα2-specific chimeric antigen receptor (CAR), IL13-zetakine [11,28]. The gene discussed is IL13RA2; the disease is glioma.